---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-111340"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2022-10-26T23:59:59+00:00"
generated_at: "2026-06-23T00:49:11.055124+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# TELA Bio publishes 24-month BRAVO study showing 2.6% recurrence rate with OviTex in hernia repair

## Summary
- BRAVO study 24-month analysis published in Annals of Medicine and Surgery; 92 patients enrolled.
- OviTex 1S Permanent demonstrated a 2.6% hernia recurrence rate at 24 months via open, laparoscopic, or robotic techniques.
- Patient quality-of-life showed statistically significant improvement from baseline at 3, 12, and 24 months.
- Surgical site occurrences in 38% of patients; 78% were high-risk (obesity, smoking, COPD, diabetes, etc.).
- CEO states commitment to ongoing BRAVO II study evaluating OviTex in robot-assisted repairs.

## SEC filing metadata
- accession: 0001104659-22-111340
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2022-10-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465922111340/0001104659-22-111340-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465922111340/tm2228895d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-111340
- JSON: https://secwatch.observer/filing/0001104659-22-111340.json
- Plain text: https://secwatch.observer/filing/0001104659-22-111340.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.